Assessment of POCD After Steep Trendelenburg Position and CO2 Pneumoperitoneum With Cerebral Oxygen
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03372135 |
Recruitment Status : Unknown
Verified October 2017 by RenJi Hospital.
Recruitment status was: Enrolling by invitation
First Posted : December 13, 2017
Last Update Posted : April 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Postoperative Cognitive Dysfunction |
Postoperative cognitive decline (POCD) is a short-term decline in cognitive function (especially in memory and executive functions) that may last from a few days to a few weeks after surgery. It is a common and impactful outcome of surgical procedures in older adults. The pathophysiology and causative mechanisms for POCD are poorly understood. It is supposed to be associated with numerous factors such as ages, trauma, inflammation, surgical stress, position, fluid, MBP, artificial pneumoperitoneum , PCO2, FiO2.
The robot-assisted radical cystectomy (RARC) is increasingly utilized. In patients undergoing RARC, Although prolonged Trendelenburg position and pneumoperitoneum can increase the cerebral blood flow, there were studies showed that the excessive cerebral perfusion can lead to encephalemia, which reduce the oxygen uptake of brain tissue and cause insufficient oxygenation of brain tissue at the cellular level. POCD may take place due to cerebral hemodynamic changes. Contemporary, intraoperative fluid restriction, a relatively long time of operation and surgical stress may also contribute to POCD.
The goal of the current study is to investigate the combined effect of this position and CO2 pneumoperitoneum on POCD during RARC with the monitor of cerebral oxygen.
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Postoperative Cognitive Deficit After Steep Trendelenburg Position and CO2 Pneumoperitoneum With Cerebral Oxygen: A Prospective Observational Pilot Study |
Actual Study Start Date : | January 1, 2017 |
Estimated Primary Completion Date : | July 1, 2018 |
Estimated Study Completion Date : | July 1, 2018 |

Group/Cohort |
---|
Trendelenburg group
Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
|
Control group
Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
|
- Diagnosis of postoperative cognitive dysfunction [ Time Frame: One week after surgery ]Using Z score method to analyse and comprehensively evaluate cognitive dysfunction scale which can help diagnosing the incidence of POCD.
- Probable risk factors of POCD [ Time Frame: 1 year ]Diagnose and screen out patients with POCD and then analyse probable factors such as MAP, CVP, trendelenburg position etc as assesed by hierarchical regression analysis.
- The effect of steep Trendelenburg position and CO2 Pneumoperitoneum on POCD [ Time Frame: 1 year ]Comparison of morbidity is made between patients underwent RARC and those who have taken surgery in horizontal position.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Chinese |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The study choose Chinese patients(ASA I - III
) above the age of 55, who will recently undergo the robot-assisted radical cystectomy. All those patients should be informed consent and be volunteered to participate in this experiment.
Those audio and visual impairment, illiteracy,existing severe central nervous system disease, patients with central nervous system disease or surgery which resulted in severe sequelae, alcohol dependence, usage of psychotropic medications, reoperative MMSE score was less than 24 should be excluded.
Inclusion Criteria:
- Above age of 55
- Will undergo the robot-assisted radical cystectomy
- informed consent, volunteered to participate in this experiment, ASA I - III
Exclusion Criteria:
- Audio and visual impairment, illiteracy
- Existing severe central nervous system disease
- Patients with central nervous system disease or surgery , resulted in severe sequelae
- Alcohol dependence
- Take psychotropic medications
- Preoperative MMSE score was less than 24

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372135
China, Shanghai | |
Renji Hospital, School of Medicine, Shanghai Jiao Tong University | |
Shanghai, Shanghai, China, 200126 |
Principal Investigator: | Jie Chen | Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | RenJi Hospital |
ClinicalTrials.gov Identifier: | NCT03372135 History of Changes |
Other Study ID Numbers: |
YYL |
First Posted: | December 13, 2017 Key Record Dates |
Last Update Posted: | April 17, 2018 |
Last Verified: | October 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
POCD RARC Trendelenburg Position |
Pneumoperitoneum Cognitive Dysfunction Cognition Disorders Neurocognitive Disorders |
Mental Disorders Peritoneal Diseases Digestive System Diseases |